Table 1 Patient characteristics according to venous thromboembolism
Overall | VTE + | VTE − | p value | |
|---|---|---|---|---|
N = 140 | N = 24 | N = 116 | ||
Gender, n (%) | ||||
Male | 97 (69.3) | 15 (62.5) | 82 (70.6) | 0.428 |
Female | 43 (31.7) | 9 (37.5) | 34 (29.3) | |
Age, median (range) | 54 (41.2–63) | 48 (38.2–57.5) | 55.5 (42–64.7) | 0.158 |
BMI, median (range) | 21 (18.7–24.1) | 21.8 (18.4–24) | 20.5 (18.7–24.1) | 0.81 |
ASA-PS ≧ 3, n (%) | 8 (5.7) | 1 (4.2) | 7 (6.0) | 0.719 |
Current smoking, n (%) | 13 (9.3) | 2 (8.3) | 11 (9.48) | 0.86 |
Preoperative therapy, n (%) | ||||
Steroid | 59 (42.1) | 13 (54.2) | 46 (39.6) | 0.19 |
Immunosuppressive agents | 48 (34.2) | 9 (37.5) | 39 (33.6) | 0.72 |
Biological agents | 20 (14.2) | 3 (12.5) | 17 (14.7) | 0.78 |
Comorbidity, n (%) | ||||
HT | 20 (14.2) | 5 (20.8) | 15 (8.6) | 0.31 |
HL | 11 (7.9) | 1 (4.2) | 10 (8.6) | 0.46 |
DM | 15 (10.7) | 0 | 15 (12.9) | 0.073 |
Indication, n (%) | ||||
Cancer/ dysplasia | 44 (31.4) | 12 (50) | 32 (27.5) | |
Refractory to medication | 96 (68.5) | 12 (50) | 84 (87.5) | 0.0313* |